Progyny, Inc. $PGNY Shares Bought by Quantbot Technologies LP

Key Points

• Quantbot Technologies LP significantly increased its holdings in Progyny, Inc. by 68.2% in the 1st quarter, owning approximately 0.17% of the company valued at $3,243,000.
• Analyst ratings for Progyny have been mixed, with one analyst upgrading the stock to a "strong-buy" rating and others setting varying price targets, reflecting a consensus rating of "Moderate Buy."
• Progyny reported quarterly earnings with an EPS of $0.19, missing estimates, but showed a revenue increase of 9.5% year-over-year, totaling $332.87 million.

Quantbot Technologies LP raised its stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 68.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 145,155 shares of the company's stock after buying an additional 58,839 shares during the quarter. Quantbot Technologies LP owned about 0.17% of Progyny worth $3,243,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC acquired a new stake in Progyny during the 1st quarter valued at $354,000. Oppenheimer Asset Management Inc. boosted its holdings in shares of Progyny by 18.7% during the first quarter. Oppenheimer Asset Management Inc. now owns 34,675 shares of the company's stock worth $775,000 after purchasing an additional 5,459 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Progyny by 233.9% during the first quarter. GAMMA Investing LLC now owns 5,379 shares of the company's stock worth $120,000 after purchasing an additional 3,768 shares during the last quarter. Cerity Partners LLC acquired a new stake in shares of Progyny during the fourth quarter worth $229,000. Finally, Voya Investment Management LLC boosted its holdings in shares of Progyny by 1.4% during the fourth quarter. Voya Investment Management LLC now owns 51,792 shares of the company's stock worth $893,000 after purchasing an additional 701 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company's stock.

Progyny Stock Performance

Shares of PGNY traded down $0.4890 during trading hours on Monday, hitting $23.0410. The stock had a trading volume of 162,298 shares, compared to its average volume of 1,404,669. The firm has a market cap of $1.98 billion, a P/E ratio of 39.03, a P/E/G ratio of 1.92 and a beta of 1.32. The company's fifty day simple moving average is $22.55 and its 200 day simple moving average is $22.17. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $26.76.

Progyny (NASDAQ:PGNY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.23). Progyny had a net margin of 4.28% and a return on equity of 10.69%. The company had revenue of $332.87 million during the quarter, compared to analysts' expectations of $315.70 million. During the same period last year, the business earned $0.17 earnings per share. The company's revenue for the quarter was up 9.5% compared to the same quarter last year. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. As a group, sell-side analysts predict that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Insider Activity

In other Progyny news, Director Cheryl Scott sold 2,675 shares of the firm's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $22.07, for a total value of $59,037.25. Following the transaction, the director directly owned 14,112 shares of the company's stock, valued at $311,451.84. This trade represents a 15.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Kevin K. Gordon sold 2,500 shares of the firm's stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $22.04, for a total value of $55,100.00. Following the completion of the transaction, the director directly owned 12,501 shares in the company, valued at $275,522.04. This trade represents a 16.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 9.40% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on PGNY. Canaccord Genuity Group raised their price objective on Progyny from $21.00 to $23.00 and gave the stock a "hold" rating in a report on Wednesday, August 20th. Cantor Fitzgerald restated an "overweight" rating and set a $28.00 price objective (up previously from $26.00) on shares of Progyny in a report on Friday, August 8th. Raymond James Financial set a $28.00 price objective on Progyny in a report on Friday, August 8th. Wall Street Zen upgraded Progyny from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Finally, Leerink Partners upgraded Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price objective on the stock in a report on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, Progyny has a consensus rating of "Moderate Buy" and an average target price of $25.10.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.